
WHAT IS CLAIMED IS:


1. A pharmaceutically acceptable salt of (*E*)-3-(4-((1*R*,3*R*)-2-(Bicyclo[1.1.1]pentan-1-yl)-3-methyl-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)acrylic acid (Compound A):



Compound A

wherein the pharmaceutically acceptable salt is a hydrosulfate salt of Compound A.

2. A pharmaceutically acceptable salt of (*E*)-3-(4-((1*R*,3*R*)-2-(Bicyclo[1.1.1]pentan-1-yl)-3-methyl-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)acrylic acid (Compound A):



Compound A

wherein the pharmaceutically acceptable salt is a sulfate salt of Compound A.

3. A pharmaceutically acceptable salt form of Compound A comprising the hydrosulfate salt of Compound A; and the sulfate salt of Compound A.

4. The pharmaceutically acceptable salt form of Claim 3 consisting essentially of the hydrosulfate salt of Compound A; and the sulfate salt of Compound A.

5. The pharmaceutically acceptable salt form of Claim 3, wherein the amount of the hydrosulfate salt of Compound A + the amount of the sulfate salt of Compound A is ≥ 85% of the pharmaceutically acceptable salt form of Compound A.

6. The pharmaceutically acceptable salt form of any one of Claims 3-5, wherein the salt form is Form A.

7. The pharmaceutically acceptable salt form of Claim 6, wherein Form A is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from a peak in the range of from about 9.4 degrees 2θ to about 9.7 degrees 2θ, a peak in the range of from about 10.2 degrees 2θ to about 10.5 degrees 2θ and a peak in the range of from about 10.9 degrees 2θ to about 11.2 degrees 2θ.


8. The pharmaceutically acceptable salt form of Claim 6, wherein the Form A is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from about 4.8 degrees 2θ ± 0.2 degrees 2θ, about 6.5 degrees 2θ ± 0.2 degrees 2θ, about 7.4 degrees 2θ ± 0.2 degrees 2θ, about 9.6 degrees 2θ ± 0.2 degrees 2θ, about 10.3 degrees 2θ ± 0.2 degrees 2θ, about 11.0 degrees 2θ ± 0.2 degrees 2θ, about 11.4 degrees 2θ ± 0.2 degrees 2θ, about 13.1 degrees 2θ ± 0.2 degrees 2θ, about 13.8 degrees 2θ ± 0.2 degrees 2θ, about 14.9 degrees 2θ ± 0.2 degrees 2θ, about 15.5 degrees 2θ ± 0.2 degrees 2θ, about 15.9 degrees 2θ ± 0.2 degrees 2θ, about 16.6 degrees 2θ ± 0.2 degrees 2θ, about 17.1 degrees 2θ ± 0.2 degrees 2θ, about 17.7 degrees 2θ ± 0.2 degrees 2θ, about 18.7 degrees 2θ ± 0.2 degrees 2θ, about 19.8 degrees 2θ ± 0.2 degrees 2θ, about 20.2 degrees 2θ ± 0.2 degrees 2θ, about 21.0 degrees 2θ ± 0.2 degrees 2θ, about 21.9 degrees 2θ ± 0.2 degrees 2θ, about 22.9 degrees 2θ ± 0.2 degrees 2θ, about 23.8 degrees 2θ ± 0.2 degrees 2θ, about 24.9 degrees 2θ ± 0.2 degrees 2θ, about 27.3 degrees 2θ ± 0.2 degrees 2θ and about 28.8 degrees 2θ ± 0.2 degrees 2θ.

9. The pharmaceutically acceptable salt form of any one of Claims 3-5, wherein the salt form is Form C.

10. The pharmaceutically acceptable salt form of any one of Claims 3-5, wherein the salt form is Form D.

11. The pharmaceutically acceptable salt form of any one of Claims 3-5, wherein the salt form is Form E.

12. A pharmaceutically acceptable salt of (*E*)-3-(4-((1*R*,3*R*)-2-(Bicyclo[1.1.1]pentan-1-yl)-3-methyl-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)acrylic acid (Compound A):



Compound A

wherein the pharmaceutically acceptable salt selected form the group consisting of a HCl salt of Compound A, a citrate salt of Compound A, a mesylate salt of Compound A, a besylate salt of Compound A, a choline salt of Compound A and an oxalate salt of Compound A.


13. The pharmaceutically acceptable salt of Claim 12, wherein the pharmaceutically acceptable salt is a HCl salt of Compound A.

14. The pharmaceutically acceptable salt of Claim 12, wherein the pharmaceutically acceptable salt is a mesylate salt of Compound A.

15. The pharmaceutically acceptable salt of Claim 12, wherein the pharmaceutically acceptable salt is a besylate salt of Compound A.

16. The pharmaceutically acceptable salt of Claim 12, wherein the pharmaceutically acceptable salt is an oxalate salt of Compound A.

17. Crystalline (*E*)-3-(4-((1*R*,3*R*)-2-(Bicyclo[1.1.1]pentan-1-yl)-3-methyl-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)acrylic acid (Compound A):



Compound A.

18. A pharmaceutical composition comprising an effective amount of the pharmaceutically acceptable salt of any one of Claims 1-17, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

19. Use of the pharmaceutically acceptable salt of any one of Claims 1-17, or the pharmaceutical composition of Claim 18, in the manufacture of a medicament for inhibiting the

growth of a cell, wherein the cell is identified as having an estrogen receptor alpha that mediates a growth characteristic of the cell.

20. Use of the pharmaceutically acceptable salt of any one of Claims 1-17, or the pharmaceutical composition of Claim 18, in the manufacture of a medicament for the treatment of a disease or condition that is estrogen receptor alpha dependent and/or estrogen receptor alpha mediated.